GSBD experienced a massive 13,155% surge in operating cash flow alongside significant portfolio turnover, with multiple debt investments being replaced across healthcare technology, software, and other sectors.

The dramatic operating cash flow increase from $2.5M to $325.7M suggests major liquidity events or asset dispositions that fundamentally altered the BDC's cash position. This level of cash generation, combined with extensive portfolio turnover (removing investments like Kaseya, Elemica, and PlanSource while adding new positions in companies like HS4 AcquisitionCo and Global Critical Logistics), indicates GSBD underwent significant strategic repositioning during this period.

GSBD delivered exceptional financial performance with net income nearly doubling from $62.9M to $119.3M (+89.7%) and operating cash flow skyrocketing by over 13,000% to $325.7M. This extraordinary cash generation, likely from major asset sales or refinancing activities, combined with strong earnings growth, signals either a major portfolio restructuring event or exceptional market conditions that allowed the BDC to monetize investments at premium valuations. The combination of surging cash flows and robust profitability suggests GSBD is in a strong position to deploy capital into new investments or return cash to shareholders.

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.